Prevalence of vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA among methicillin-resistant S. aureus with high vancomycin minimal inhibitory concentrations in Taiwan: A multicenter surveillance study, 2012–2013  by Huang, Sung-Hsi et al.
Journal of Microbiology, Immunology and Infection (2016) 49, 701e707Available online at www.sciencedirect.com
ScienceDirect
journal homepage: www.e- jmii .comORIGINAL ARTICLEPrevalence of vancomycin-intermediate
Staphylococcus aureus (VISA) and
heterogeneous VISA among methicillin-
resistant S. aureus with high vancomycin
minimal inhibitory concentrations in
Taiwan: A multicenter surveillance study,
2012e2013
Sung-Hsi Huang a, Yee-Chun Chen a, Yin-Ching Chuang b,
Sheng-Kang Chiu c, Chang-Phone Fung d, Po-Liang Lu e,
Lih-Shinn Wang f, Tsu-Lan Wu g, Jann-Tay Wang a,*a Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
b Department of Medical Research, Chi Mei Medical Center, Tainan County, Taiwan
c Division of Infectious Diseases and Tropical Medicine, Department of Medicine, Tri-Service General
Hospital, National Defense Medical Center, Taipei, Taiwan
d Section of Infectious Diseases, Department of Medicine, Taipei Veterans General Hospital, National
Yan-Ming University, Taipei, Taiwan
e Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
f Department of Infectious Diseases, Buddhist Tzu Chi General Hospital, Hualien, Taiwan
g Department of Laboratory Medicine, Chang Gung Memorial Hospital, Kweishan, Taoyuan, TaiwanReceived 8 April 2015; received in revised form 12 June 2015; accepted 6 July 2015
Available online 31 July 2015KEYWORDS
epidemiology;
heterogeneous
vancomycin-
intermediate* Corresponding author. Department
Taiwan.
E-mail address: wang.jt1968@gma
http://dx.doi.org/10.1016/j.jmii.2015
1684-1182/Copyright ª 2015, Taiwan
CC BY-NC-ND license (http://creativeAbstract Background/Purpose: Intermediate-resistance and heteroresistance to vancomycin
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study in 2003 showed that the prevalence rates of vancomycin-intermediate S. aureus (VISA)
and heterogeneous VISA (hVISA) in Taiwan were 0.2% and 0.7%, respectively. This study aimed
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aureus;
TaiwanMethods: MRSA isolates from sterile sites with minimal inhibitory concentrations (MICs) of
1 mg/mL or more to vancomycin were collected from 15 participating hospitals in Taiwan.
Enrolled MRSA isolates were submitted to antimicrobial susceptibility testing, staphylococcal
cassette chromosome mec (SCCmec) element typing, and multilocus sequence typing. Isolates
with vancomycin MIC of 1 mg/mL or 2 mg/mL were screened for vancomycin heterogeneous
resistance by Etest glycopeptide-resistance detection (GRD). Those with positive GRD
screening results were then analyzed by modified population analysis profiling-area under
the curve method for confirmation of vancomycin heteroresistance.
Results: Between 2012 and 2013, a total of 622 MRSA isolates from sterile sites with vancomy-
cin MIC of 1 mg/mL or more were studied. The prevalence rates of hVISA and VISA among these
isolates were 10.0% and 2.7%, respectively. The hVISA prevalence increased significantly
compared to that in 2003. Compared with vancomycin-susceptible S. aureus, hVISA and VISA
isolates were less susceptible to ciprofloxacin, clindamycin, daptomycin, gentamicin,
rifampin, and trimethoprim/sulfamethoxazole, and are thus, more likely to have SCCmec II
or III element. A twofold increase in either vancomycin or teicoplanin MIC doubled the proba-
bility of being hVISA.
Conclusion: Growing hVISA prevalence was highly suspected. Longitudinal surveillance of this
phenomenon and monitoring of its clinical impact are necessary.
Copyright ª 2015, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction
Staphylococcus aureus is one of the most common human
pathogens, which causes a broad spectrum of illnesses
ranging from relatively mild skin infection to life-
threatening septicemia.1 As with other major human path-
ogens, antimicrobial resistance of S. aureus emerged along
with the discovery and widespread use of different classes of
antibiotics.2 Among these, resistance to methicillin is of
most concern because it leads to resistance to all b-lactams,
the antibiotics most commonly used clinically; additionally,
methicillin-resistant S. aureus (MRSA) infection is associated
with significantly additional morbidity and mortality.3 The
prevalence of MRSA infection has increased during the past
decades and in some areas its prevalence has been reported
to be over 50%.4 This has resulted in an increased use of
glycopeptides such as vancomycin, which have been the
treatment of choice for MRSA infection for decades.
The first strain of MRSA with reduced vancomycin sus-
ceptibility was reported in Japan in 1997.5 Vancomycin-
resistant S. aureus (VRSA) infection remains rare to this
date,6,7 but vancomycin-intermediate S. aureus (VISA) and
heterogeneous VISA (hVISA) are encountered more
commonly. In the initial Japanese study in 1997, 5e26% of
MRSA isolates from various university hospitals were hVISA.8
Later publications reported that the prevalence of hVISA
ranged from 0% to 22.1% (of all MRSA isolates) with marked
geographic variation.9,10 By contrast, the VISA prevalence
rate was generally lower than 1% across the globe.11e14
Infections caused by hVISA and VISA were associated with
vancomycin treatment failure and prolonged duration of
treatment and hospitalization compared with those caused
by vancomycin-susceptible S. aureus (VSSA).15,16 The Clin-
ical and Laboratory Standard Institute (CLSI) lowered the
vancomycin minimal inhibitory concentration (MIC) break-
point (from 4 mg/mL to 2 mg/mL for susceptible andfrom 32 mg/mL to 16 mg/mL for resistant strains) in 2006
to reflect the growing body of evidence that isolates with
vancomycin MIC of 4 mg/mL or more are less likely to
respond to vancomycin therapy.
There have been few studies investigating the epide-
miology of hVISA and VISA in Taiwan: a network survey
including 1000 MRSA isolates from 10 medical centers in
2003 showed that the prevalence rate of VISA and hVISA had
been low,11 whereas one small-sized single center study
revealed an increasing burden of hVISA in 2009.17 Using a
larger sample collected from across Taiwan, we aimed to
determine the recent prevalence of hVISA and VISA among
MRSA isolates with vancomycin MICs of 1 mg/mL or more in
Taiwan and identify the characteristics of these isolates
with heteroresistance or intermediate resistance to
vancomycin.Methods
Bacterial isolates
The study period was from January 2012 to December 2013.
In each year, MRSA isolates from sterile sites, including
blood, cerebrospinal fluid, ascites, and pleural effusion,
with vancomycin MIC of 1 mg/mL or more determined at
their source hospitals, were collected consecutively since
January 1 from 15 participating hospitals. The preset
numbers of bacterial isolates enrolled each year was 300.
When the total number of collected MRSA isolates reached
300 in each year, the participating hospital would be
informed to stop submitting further samples for that year.
Duplicated isolates would be excluded. The 15 participating
hospitals included 12 medical centers and three regional
hospitals distributed in northern (6 hospitals), central (2
hospitals), southern (5 hospitals), and eastern (2 hospitals)
Prevalence of VISA and hVISA in Taiwan 703Taiwan. The collected MRSA isolates were sent to the
central laboratory located at National Taiwan University
Hospital (NTUH). Only those isolates confirmed to be MRSA
and had vancomycin MIC of 1 mg/mL or more by broth
dilution method performed in the central laboratory were
formally enrolled for subsequent microbiological studies.
All isolates were preserved at 80C before the microbio-
logical studies.Microbiological studies
Antimicrobial susceptibility testing by MIC
The MICs to 12 antibiotics (ciprofloxacin, clindamycin,
daptomycin, erythromycin, gentamicin, linezolid, oxacillin,
rifampicin, teicoplanin, tetracycline, trimethoprim/sulfa-
methoxazole, and vancomycin) were determined by broth
microdilution method using custom-designed 96-well panels
(Sensititre Vizion Digital MIC Viewing System, Thermo Sci-
entific, West Sussex, UK). The result was interpreted
following the CLSI guidelines. Of note, isolates with van-
comycin MIC of 4e8 mg/mL were defined as VISA.18
Etest glycopeptide-resistance detection
Each enrolled MRSA isolate with vancomycin MIC of 1 mg/mL
or 2 mg/mL was screened for hVISA using Etest glycopeptide-
resistance detection (GRD), which has been described
earlier with 93% sensitivity compared with the population
analysis profiling-area under the curve (PAP-AUC) method.19
The test was performed according to the manufacturer’s
instruction (Etest GRD for screening of heterogeneous
glycopeptide-intermediate S. aureus/glycopeptide-inter-
mediate S. aureus, bioMe´rieux SA, Lyon, France). In brief, a
bacterial suspension corresponding to a 0.5 McFarland
standard was grown on a Mu¨llereHinton agar þ 5% blood
(MHB; Becton, Dickinson and Company, Sparks, MD, USA)
plate. A GRD strip consisting of a double-sided gradient with
vancomycin and teicoplanin was then applied to the MHB
plate. The zone of the Etest GRD strip was read at complete
inhibition of growth 24 hours and 48 hours after incubation.
The test isolate was considered positive for hVISA if the Etest
GRD strip result was 8 mg/mL or more for either vancomycin
or teicoplanin.
Modified PAP-AUC
All isolates screenedpositivebyE-testGRDwere subsequently
tested with modified PAP-AUC method as described pre-
viously.20e22 In brief, a 0.5 McFarland standard suspension
from an overnight culture of the isolate to be tested in Tryp-
ticase soy broth agar (Becton Dickinson and Company) was
prepared. Serial dilutions (101 to 106) were prepared in
sterile saline, and100mLof 106 dilutionswereplatedbyhand
onto braineheart infusion (BHI) agar (Becton, Dickinson and
Company) to determine viable counts. Four 10-mL droplets
fromeachoffivedilutions (101 to105)werethenaddedonto
BHI agar plates containing increasing concentrations of van-
comycin (0 mg/L, 0.25 mg/L, 0.5 mg/L, 0.75 mg/L, 1 mg/L,
1.5 mg/L, 2 mg/L, 3 mg/L, 4 mg/L, 6 mg/L, and 8 mg/L) and
readafter 24hours and48 hours of incubationat 35C.All PAP-
AUCmethods were performed using Mu3 as a positive control.
Interpretation of PAP-AUC was as follows: ratio of the AUC of
the test isolate to Mu3 of 0.9 or more and less than 1.3 wasconsidered hVISA,23 ratio of the AUC of the test isolate to Mu3
of 1.3 or more was considered VISA, and the rest was consid-
ered VSSA.
Determination of staphylococcal cassette chromosome
mec typing and multilocus sequence typing using
polymerase chain reaction-based methods
All the studied isolates were submitted to staphylococcal
cassette chromosome mec (SCCmec) typing and multilocus
sequence typing (MLST) as described earlier.24,25 MRSA
isolates carrying type I, II, or III SCCmec element were
classified as health-care-associated MRSA (HA-MRSA), and
those carrying type IV or V as community-associated MRSA
(CA-MRSA).26Statistic analysis
The enrolled isolates were categorized into three groups,
namely, VSSA, hVISA, and VISA. Their antibiotic suscepti-
bility and molecular typing were compared. Statistical an-
alyses were performed using SAS statistical software
(Version 9.2, SAS Institute Inc., Cary, NC, USA). Continuous
variables were compared by the ManneWhitney U test or
Student t test, and categorical variables were compared by
Chi-square test or Fisher exact test. Selected variables,
including year of the isolates; SCCmec II or III (indicating
HA-MRSA); susceptibility to ciprofloxacin, clindamycin,
daptomycin, gentamicin, rifampin, and trimethoprim/sul-
famethoxazole; and MIC of vancomycin and teicoplanin in
binary logarithm, were used for a stepwise backward
regression analysis to determine the association with risk of
hVISA and VISA. A p value less than 0.05 was considered
significant. All tests were two-tailed.Results
A total of 678 bacterial isolates were sent to the central
laboratory at NTUH between 2012 and 2013. Among them,
39 isolates were reidentified as methicillin-susceptible
S. aureus, 17 isolates were found to have vancomycin MIC
of 0.5 mg/mL or less, and 13 isolates were VISA (vancomycin
MIC Z 4 mg/mL in 11 isolates and 8 mg/mL in 2 isolates).
Methicillin-susceptible S. aureus and MRSA isolates with
vancomycin MIC of 0.5 mg/mL or less were excluded. For
the remaining 622 MRSA isolates with vancomycin MIC of
1 mg/mL or more, 386 came from the six hospitals in
Northern Taiwan, 37 from the two hospitals in Central
Taiwan, 179 from the five hospitals in Southern Taiwan, and
26 from the two hospitals in Eastern Taiwan. None of the
isolates expressed full vancomycin resistance according to
CLSI breakpoint.
Antimicrobial susceptibility testing on these isolates
revealed that daptomycin, linezolid, and teicoplanin
remained highly active against MRSA with susceptibility rate
of 95%, 99.5%, and 99.5% respectively, whereas ciprofloxa-
cin, clindamycin, erythromycin, tetracycline, and trimetho-
prim/sulfamethoxazole had a susceptibility rate between 9%
and 46.1% and were generally much less reliable (Table 1).
The VISA isolates exhibited resistance to most tested anti-
microbials but were universally susceptible to linezolid.
Table 1 Antimicrobial susceptibility of MRSA isolates categorized according to vancomycin susceptibility.
Antimicrobial agent VSSA
(N Z 543)
hVISA
(N Z 62)
VISA
(N Z 17)
Total
(N Z 622)
p* p**
%S %I %R %S %I %R %S %I %R %S %I %R
Ciprofloxacin 29.7 4.6 65.7 9.7 1.6 88.7 11.8 0 88.2 27.2 4.2 68.6 0.001 <0.001
Clindamycin 27.1 5.7 67.2 12.9 4.8 82.3 5.9 0 94.1 25.1 5.5 69.5 0.02 0.003
Daptomycin*** 96.7 3.3 88.7 11.3 64.7 35.3 95 5 <0.001 <0.001
Erythromycin 9.6 6.4 84 4.8 3.2 91.9 5.9 0 94.1 9 5.9 85 0.57 0.166
Gentamicin 20.3 3.9 75.9 8.1 1.6 90.3 5.9 0 94.1 18.6 3.5 77.8 0.056 0.005
Linezolid 99.8 e 0.4 98.4 e 1.6 100 e 0 99.5 e 0.5 0.339 0.355
Rifampin 82.5 11.4 6.1 66.1 19.4 14.5 52.9 17.6 29.4 80.1 12.4 7.6 0.001 <0.001
Teicoplanin 99.8 0 0.2 100 0 0 88.2 0 11.8 99.5 0 0.5 0.003 0.029
Tetracycline 31.5 1.1 67.4 19.4 0 80.6 17.6 0 82.4 29.9 1 69.1 0.195 0.052
Trimethoprim/
sulfamethoxazole
49.5 e 50.5 24.2 e 75.8 15.4 e 84.6 46.1 e 53.9 <0.001 <0.001
hVISA Z heterogeneous vancomycin-intermediate Staphylococcus aureus; MRSA Z methicillin-resistant Staphylococcus aureus;
VISA Z vancomycin-intermediate Staphylococcus aureus; VSSA Z vancomycin-susceptible S. aureus.
* Fisher exact test for distribution of susceptibility between VSSA, hVISA, and VISA.
** Fisher exact test for distribution of susceptibility between vancomycin-susceptible (VSSA) and nonsusceptible isolates (hVISA and
VISA).
*** The number of percentage is reported as %R, which represents nonsusceptible rate.
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Figure 1. Distribution of teicoplanin minimum inhibitory
concentrations (MICs) in vancomycin-susceptible Staphylo-
coccus aureus (VSSA), heterogeneous vancomycin-
intermediate S. aureus (hVISA), and vancomycin-intermediate
S. aureus (VISA) isolates.
704 S.-H. Huang et al.Etest GRD was performed on all the 609 isolates with
vancomycin MICs of 1 mg/mL or 2 mg/mL. Among these
isolates, 150 had either vancomycin or teicoplanin MIC of
8 mg/mL or more and were further examined by modified
PAP-AUC method. Finally, 62 isolates (10%) were identified
as hVISA as they had AUC of the test isolate to Mu3 ratio of
0.9 or more and less than 1.3, compared with the Mu3
reference strain. Of note, four isolates examined by the
PAP-AUC method had AUC of the test isolate to Mu3 ratio of
1.3 or more of the Mu3 strain. These isolates were reclas-
sified as VISA in the subsequent analysis. Among the 62
hVISA isolates, 48 had a vancomycin MIC of 2 mg/mL (48/
270, 17.8%) and 14 had a vancomycin MIC of 1 mg/mL (14/
355, 4.2%).
All 622 isolates underwent SCCmec element typing and
MLST genotyping. Of the 561 isolates with typable SCCmec,
more than half (312/561, 55.6%) had SCCmec III, whereas
SCCmec II, SCCmec IV, and SCCmec V accounted for 9.8%,
16.2%, and 18.4% of the isolates, respectively. Of the 499
VSSA isolates with typable SCCmec, 61.7% of the isolates
belonged to molecularly defined HA-MRSA strains (carrying
SCCmec II and III). In comparison, 12 of 15 (80.0%) VISA
isolates and 47 of 57 (82.5%) hVISA isolates belonged to
molecularly defined HA-MRSA strains. The result from MLST
genotyping showed that the most common sequence type
(ST) among MRSA isolates was ST239 (50.9%), followed by
ST59, ST5, and ST45. Seventeen other minor STs, including
ST508, ST188, ST573, ST6, ST97, ST1149, ST15, ST22, ST72,
ST241, ST338, ST672, ST1454, and ST1598, accounted for
the rest 11.9% of the isolates. The ST distribution did not
differ significantly among VSSA, hVISA, and VISA isolates
(p Z 0.181).
Upon comparing drug susceptibilities between VSSA
(n Z 543), hVISA isolates (n Z 62), and VISA (n Z 17), the
VSSA isolates were significantly more susceptible to cipro-
floxacin, clindamycin, daptomycin, gentamicin, rifampin,
and trimethoprim/sulfamethoxazole (Table 1). Linezolidand daptomycin were highly active in vitro against most
MRSA isolates, including the hVISA isolates. However, 35.3%
of VISA isolates were nonsusceptible to daptomycin. The
distribution of teicoplanin MICs stratified by vancomycin
susceptibility is shown in Figure 1. The MRSA isolates with
higher teicoplanin MICs, especially those with MICs of 2 mg/
mL or more, were more likely to exhibit heteroresistance
and intermediate resistance to vancomycin (Figure 2).
In the attempts to identify factors associated with hVISA
and VISA that were identified by the PAP-AUC method, the
MRSA isolates with vancomycin MICs of 1 mg/mL and 2 mg/
mL (609 isolates) were included in a multivariate logistic
regression analysis. The result showed that a twofold
Figure 2. Proportion of vancomycin-intermediate Staphylo-
coccus aureus (VISA), heterogeneous vancomycin-intermediate
S. aureus (hVISA), and vancomycin-susceptible S. aureus (VSSA)
in methicillin-resistant S. aureus (MRSA) isolates with different
teicoplanin minimum inhibitory concentrations (MICs). aThere
were only a total of five and three isolates with teicoplanin MIC
of 8 mg/mL and 16 mg/mL or more, respectively.
Table 2 Logistic regression model for factors associated
with hVISA.
Odds ratio (95%
confidence interval)
p
MIC of vancomycin
in binary logarithm
2.274 (1.140e4.539) 0.02
MIC of teicoplanin
in binary logarithm
2.397 (1.660e3.460) <0.001
hVISA, heterogenous vancomycin-intermediate Staphylococcus
aureus; MIC Z minimum inhibitory concentration.
Prevalence of VISA and hVISA in Taiwan 705increase in MIC of teicoplanin or vancomycin doubled the
risk for the isolate to be identified as hVISA (Table 2).
Despite the association, incorporating both vancomycin and
teicoplanin MIC of 2 mg/mL or more as a screening tool did
not significantly improve the value in predicting hVISA and
VISA compared with using vancomycin MIC of 2 mg/mL or
more alone (Table 3).Table 3 Sensitivities and specificities of different strategies in
hVISA.
Sensitivity
Vancomycin MIC  2 mg/mL 78.8%
Teicoplanin MIC  2 mg/mL 53%
Either vancomycin or teicoplanin MIC  2 mg/mL 83.3%
Both vancomycin and teicoplanin MIC  2 mg/mL 48.5%
Comparison
Etest GRD at 48 h19 93%
Macro Etest at 48 h19 83%
GRD Z glycopeptide-resistance detection; hVISA Z heterogenous v
inhibitory concentration; NPV Z negative predictive value; PPV Z poDiscussion
In this surveillance study, we systemically collected MRSA
isolates from sterile sites with vancomycin MICs of 1 mg/mL
or more in a 2-year period and applied standard methods to
detect hVISA and VISA for all enrolled isolates. The isolates
came from 15 different medical centers in four different
parts of Taiwan. Thus, our results should be more repre-
sentative of local epidemiology in Taiwan. Among the 622
MRSA isolates with vancomycin MIC of 1 mg/mL or more, 17
(2.7%) VISA isolates and 62 (10.0%) hVISA isolates were
identified.
A wide range of prevalence of hVISA has been reported
and the prevalence varied between different geographic
area, source of isolates, and detection methods. hVISA
isolates generally accounted for a substantial portion of
MRSA among Asian countries (16.5% from 830 blood-borne
MRSA isolates in Japan, 11.1% from 1175 various clinical
isolates in 14 Chinese hospitals, and 22.1% from 184 sterile
site isolates in China).10,27,28 One previously published
epidemiological study in Taiwan reported an hVISA preva-
lence of only 0.7% in 2003.11 Another previous single-center
observation study from Southern Taiwan showed the prev-
alence rate of 4.2% among MRSA blood isolates in 2009. Our
study only enrolled MRSA isolates with vancomycin MIC of
1 mg/mL or more, and the result showed that the hVISA
prevalence among them was 10.0%. Between 2006 and
2010, the proportion of MRSA with vancomycin MIC of
0.5 mg/mL or less among all MRSA isolates from sterile sites
was reported to be 2.4%.29 Accordingly, the estimated
hVISA prevalence, based on available data, among MRSA
isolates with vancomycin MIC of 1 mg/mL or more in 2003
and 2009 would be approximately 0.7% and 4.3%, respec-
tively, which were still lower than 10.0%. In addition, our
data showed an alarming VISA prevalence rate of 2.7%,
which is higher than that reported worldwide (<1%).11e14
While the difference could be related to different enroll-
ment criteria or different screening methods, an evolution
of the pathogen to become more resistant to vancomycin is
also highly possible. The increase of hVISA prevalence rate
and reduced vancomycin susceptibility among MRSA iso-
lates should raise caution.
There is evidence that hVISA and VISA are associated with
vancomycin treatment failure, persistent bacteremia, longer
hospital stay, and adverse final clinical outcome.15,30,31 While
glycopeptides remained the first-line treatment for MRSAcorporating vancomycin and teicoplanin MIC in prediction of
Specificity PPV NPV Sensitivity þ specificity
59.1% 19% 95.8% 1.379
83.8% 28.5% 93.6% 1.368
55.6% 18.6% 96.5% 1.389
87.3% 31.7% 93.3% 1.358
82%
94%
ancomycin-intermediate Staphylococcus aureus; MIC Z minimal
sitive predictive value.
706 S.-H. Huang et al.infection, more judicious use of vancomycin and teicoplanin,
along with appropriate dosing regimen, regular therapeutic
drug monitoring, adequate infection source control, and
strategies to prevent further nosocomial transmissions would
be required to prevent treatment failure in an increasingly
vancomycin hetero-resistant microenvironment.32
It is well-known that HA-MRSA is generally more resistant
to multiple non-b-lactams antimicrobials compared with
CA-MRSA. Most hVISA and VISA isolates in this study
belonged to molecularly defined HA-MRSA and were highly
resistant to a broad spectrum of antimicrobials compared
with VSSA, consistent with prior publications.17,21,33 The
current mainstream theory postulates that heterogeneous
and intermediate vancomycin resistances evolve in a step-
wise process and are related to higher background antibi-
otic selection pressure and infection sites that are more
difficult to treat.34 In this context, it is reasonable that the
hVISA and VISA isolates in this study were found to be more
likely to be molecularly defined HA-MRSA.
Still, a certain percentage of hVISA isolates in our study
belonged to molecularly defined CA-MRSA. This phenome-
non has not been shown in a prior Taiwanese epidemio-
logical study,17 but a prior large-scale study in Chicago did
demonstrate that CA-MRSA can harbor vancomycin heter-
oresistance.30 Therefore, heteroresistance to vancomycin
should also be taken into consideration when the clinical
response is inadequate while using vancomycin to treat CA-
MRSA infection, and the use of linezolid or daptomycin
should be considered in this situation. We also noticed a
decreased daptomycin susceptibility in hVISA and VISA
isolates compared with VSSA isolates. Similar observations
have been reported and current hypothesis suggests that
this phenomenon could be related to the thickening of
bacterial cell wall.34,35 The resistance to daptomycin
should thus be continuously monitored.
The standard method to detect hVISA, the PAP-AUC
method, is time consuming, labor intensive, and not
routinely available and thus has its limitation. Microbiology
laboratories use different screening strategies, including
Etest macromethod, Etest GRD, and BHI screening agar
containing 3e4 mg/mL of vancomycin to identify hVISA. All
of the screening methods still required extra work, man
power, and training. In one report, Etest macromethod and
Etest GRD had good specificity but limited sensitivity (57%),
whereas methods using BHI screening were highly sensitive
but less specific (67e94%).20 In this study, the test using
simple screening methods such as teicoplanin and vanco-
mycin MIC failed to provide convincing prediction of hVISA.
A simpler, but yet more accurate, diagnostic method still
awaits discovery.
This study had several limitations. First, the study was
aimed to provide epidemiological surveillance data, and
thus, it lacked important clinical information outside of
microbiology laboratories. Second, despite good sensitivity
of Etest GRD,19 certain portion of hVISA would still be false
negative during screening process. Furthermore, although
it has been reported that MRSA isolates with vancomycin
MIC of 0.5 mg/mL or less accounted for only a small portion
of all MRSA isolates in Taiwan,29,36 and the prevalence of
hVISA among these isolates is expected to be quite low,37,38
our study only enrolled MRSA isolates with vancomycin MIC
of 1 mg/mL or more, which would likely overestimate thehVISA prevalence among all MRSA isolates. Therefore, our
result should be interpreted and applied conservatively.
In conclusion, the prevalence of hVISA and VISA among
MRSA isolates from sterile sites and with vancomycin MIC of
1 mg/mL or more in Taiwan was 10.0% and 2.7%, respec-
tively. The hVISA prevalence probably increased compared
with prior reports. In addition, heteroresistance to vanco-
mycin was noted among CA-MRSA isolates in our study. The
burden and clinical impact of hVISA and VISA should be
closely and continuously monitored.Conflicts of interest
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